Please select the eligibility criteria that correspond to the clinical trial below.
Title: OPTImal CArdiac REhabilitation (OPTICARE)Following Acute Coronary Syndromes: A Randomized, Controlled Trial to Investigate the Benefits of an Expanded Educational and Behavioural Intervention Program.
Brief Summary: The objective is to investigate whether in acute coronary syndrome patients the cardiac risk profile will improve with 2 new extended cardiac rehabilitation interventions and if these patients maintain healthier life style habits and a more active life style compared to patients randomized to standard cardiac rehabilitation.


Options:
A: Inclusion Criteria:

* Two months to 10 years from the cardiovascular event.
* Left ventricular ejection fraction \> 30%
* Ability to undertake regular physical activity (walking and biking)

Exclusion Criteria:

* Moderate to severe heart valvular disease.
* Atrial fibrilation.
* Uncontrolled atrial or ventricular arrhythmias.
* Exercise induced myocardial ischaemia.
* Pericardial disease.
* Uncontrolled hypertension.
* Insulin dependent diabetes mellitus.
* Moderate to severe chronic lung disease (Vital capacity and/or forced expiratory volume during the first second \<80% to that expected for the age).
* Severe kidney disease (renal creatinine clearance \<30 mL/min, calculated by Cockcroft-Gault formula).
* Anaemia (haemoglobin \<12 g/dL).
* Life expectancy less than one year.
B: Inclusion Criteria:

* Patients with an acute coronary syndrome treated with primary or elective PCI or coronary surgery (CABG), with a stable medical condition and providing written informed consent are eligible to participate.
* Men and women who signed informed consent.
* Patients are eligible to participate in the study if they are: able to regularly attend a supervised exercise programme and able to complete Dutch language questionnaires.

Exclusion Criteria:

* Patients with heart failure
* Impaired left ventricular function (LVEF\<40%)
* Psychic or cognitive impairments
* Severe arrhythmias
* Heart valve disease
* Congenital disease
* Severe co-morbidities which limit the CR (e.g. severe COPD, severe diabetes or locomotive disorder) and patients with an ICD will be excluded.
C: Inclusion Criteria:

* Class I to III angina pectoris (classified according to the Canadian Cardiovascular Society \[CCS\])with documented myocardial ischemia or coronary artery disease on angiography
* Ability to read and speak English to a level allowing satisfactory completion of written questionnaires and to understand instruction during the exercise programme.

Exclusion Criteria:

* Acute coronary syndromes or recent myocardial infarction (\<2 months)
* Left main coronary artery stenosis \>25% or high-grade proximal left anterior descending artery stenosis
* Known reduced left ventricular function (ejection fraction \<40%)
* Significant valvular heart disease
* Insulin-dependent diabetes mellitus
* Occupational, orthopedic, and other conditions that preclude regular exercise
* Patients whose ECG prevents interpretation of an exercise test (LBBB, RBBB, pacemaker implantation).
* Patients who already perform greater than 30min continuous exercise three times weekly (self-reported).
D: Inclusion Criteria:

1. Presence of MI who has successful revascularization after the symptom onset;
2. Aged 18 years or over and under 80 years;
3. Availability to attend sessions twice a week over a 12-week period;
4. Physical aptitude to participate in a Baduanjin exercise -based cardiac rehabilitation program.

Exclusion Criteria:

1. Inability or difficulty to exercise
2. Prior history of practicing Qigong (Taiji or Baduanjin exercise, etc);
3. Presence of unstable angina, detectable myocardial ischemia (at rest or on exertion), significant valvular disease, and hypertrophic cardiomyopathy;
4. Severe symptomatic congestive heart failure (NYHA cardiac function class IV or left ventricular ejection fraction≤35%);
5. Severe pulmonary disease, musculoskeletal system diseases, other comorbidities precluding physical activity;
6. Life-threatening diseases with limited life expectancy \<1 year;
7. Pregnant and lactating women;
8. Participation in other clinical trials.

Answer: B